Compare · NTRA vs OMI
NTRA vs OMI
Side-by-side comparison of Natera Inc. (NTRA) and Owens & Minor Inc. (OMI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NTRA and OMI operate in Medical Specialities (Health Care), so they compete in similar markets.
- NTRA is the larger of the two at $37.52B, about 11.5x OMI ($3.27B).
- Over the past year, NTRA is up 89.7% and OMI is down 64.4% - NTRA leads by 154.1 points.
- NTRA has hit the wire 11 times in the past 4 weeks while OMI has been quiet.
- NTRA has more recent analyst coverage (25 ratings vs 12 for OMI).
- Company
- Natera Inc.
- Owens & Minor Inc.
- Price
- $261.88-1.03%
- $2.79+1.82%
- Market cap
- $37.52B
- $3.27B
- 1M return
- +0.74%
- +4.68%
- 1Y return
- +89.70%
- -64.44%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2015
- News (4w)
- 11
- 0
- Recent ratings
- 25
- 12
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Owens & Minor Inc.
Owens & Minor, Inc., together with its subsidiaries, operates as a healthcare solutions company in the United States and internationally. It operates through two segments, Global Solutions and Global Products. The Global Solutions segment offers a portfolio of products and services to healthcare providers and manufacturers. Its portfolio of medical and surgical supplies includes branded products and its proprietary products. This segment also offers services to healthcare providers, which include supplier management, analytics, inventory management, and clinical supply management; and various programs to provide logistics and marketing solutions to its suppliers. The Global Products segment manufactures and sources medical surgical products for the prevention of healthcare-associated infections across the acute and alternate site channels. This segments products portfolio includes sterilization wraps, surgical drapes and gowns, facial protection products, protective apparel, medical exam gloves, custom and minor procedure kits, and other medical products. The company provides its products and services to multi-facility networks of healthcare providers, independent hospitals, surgery centers, physicians' practices, and networks of hospitals directly, as well as indirectly through third-party distributors. Owens & Minor, Inc. was founded in 1882 and is headquartered in Richmond, Virginia.
Latest NTRA
- Signatera™ MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study
- Director Chapman Rowan E sold $37,101 worth of shares (135 units at $274.82) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 4,663 units (SEC Form 4)
- CO-FOUNDER Sheena Jonathan sold $410,825 worth of shares (1,500 units at $273.88) as part of a pre-agreed trading plan (SEC Form 4)
- Finalized MolDx LCD Includes Expanded Coverage for Natera’s Prospera™ Portfolio
- CO-FOUNDER Sheena Jonathan sold $836,898 worth of shares (3,150 units at $265.68) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 246,202 units (SEC Form 4)
- Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers
- EXECUTIVE CHAIRMAN Rabinowitz Matthew sold $280,000 worth of shares (1,000 units at $280.00) as part of a pre-agreed trading plan (SEC Form 4)
- SEC. AND CHIEF LEGAL OFFICER Rabinowitz Daniel sold $4,574,431 worth of shares (16,800 units at $272.29) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 172,294 units (SEC Form 4)
- PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold $818,710 worth of shares (3,000 units at $272.90) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 134,643 units (SEC Form 4)
- Natera Inc. filed SEC Form 8-K: Leadership Update
Latest OMI
- Amendment: Owens & Minor Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- Owens & Minor Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure
- Owens & Minor, Inc. Completes Sale of Products & Healthcare Services Business to Platinum Equity
- Owens & Minor Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure
- Owens & Minor Announces Corporate Name Change to Accendra Health, Inc.
- Owens & Minor Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Owens & Minor Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Owens & Minor to Present at Upcoming Investor Conferences on December 2, 2025
- EVP, CEO P&HS Long Andrew G gifted 47,908 shares, decreasing direct ownership by 18% to 214,064 units (SEC Form 4)
- Owens & Minor downgraded by UBS with a new price target